Ramdev Released Research Paper On Coronil

New Delhi : Yoga Guru Ramdev, the founder of Patanjali, released the first scientific research paper on the evidence-based medicine for COVID-19 by his organization. Union Health Minister, Dr Harsh Vardhan, and Union Minister Nitin Gadkari were also present at the event.

The medicine for which the data has been released is named Coronil. In June last year, Patanjali claimed that its Ayurvedic medicine can cure coronavirus infection. Following some controversy on the claims, Patanjali’s Coronil Kit was licensed as an ‘immunity booster’.

Swami Ramdev, at the event, said, that people believe that research work can only be conducted in the West. Especially when it comes to Ayurveda, people look at research work with suspicion. He also said that Coronil has benefited lakhs of people during the pandemic.

In June 2020, Patanjali Ayurved had launched ‘Coronil and Swasari’, which the company claimed was the first Ayurvedic cure for COVID-19, the respiratory disease caused by the novel coronavirus or SARS-CoV-2 virus. Launching a kit of three Ayurvedic medicines at Patanjali Yogpeeth in Haridwar, Uttarakhand, Yoga guru Ramdev had said they are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS.

Ramdev had also said that the medicine could provide ‘100 per cent recovery rate within 3-7 days’.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’